ACRO Biomedical Co Stock

ACRO Biomedical Co EBIT

The EBIT of ACRO Biomedical Co (ACBM) as of Jul 26, 2026 is -154,000.00 USD. In the previous year, EBIT was -38,000.00 USD — a change of 305.26% (lower).

EBIT

-154,000.00USD

YoY

305.26%

Last updated:

In 2026, ACRO Biomedical Co's EBIT was -154,000.00 USD, a 305.26% increase from the -38,000.00 USD EBIT recorded in the previous year.

The ACRO Biomedical Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (k USD)
Date
EBIT (k USD)
Jan 1, 2018
520.00 base
Jan 1, 2019
-440.00 base
Jan 1, 2020
-130.00 base
Jan 1, 2021
-7,690.00 base
Jan 1, 2022
-15,870.00 base
Jan 1, 2023
-8,804.40 base
Jan 1, 2024
-38.00 base
Jan 1, 2025
-154.00 base
YEAREBIT (k USD)
2025 -154.00
2024 -38.00
2023 -8,804.40
2022 -15,870.00
2021 -7,690.00
2020 -130.00
2019 -440.00
2018 520.00
2017 -
2016 -40.00
2015 -50.00
2014 -
2013 -
Access this data via the Eulerpool API

ACRO Biomedical Co Revenue

ACRO Biomedical Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
8.01 M USD
520,000.00 USD
420,000.00 USD
Jan 1, 2019
1.35 M USD
-440,000.00 USD
-370,000.00 USD
Jan 1, 2020
690,000.00 USD
-130,000.00 USD
-120,000.00 USD
Jan 1, 2021
1.20 M USD
-7.69 M USD
-7.70 M USD
Jan 1, 2022
660,000.00 USD
-15.87 M USD
-15.87 M USD
Jan 1, 2023
0.00 USD
-8.80 M USD
-8.81 M USD
Jan 1, 2024
0.00 USD
-38,000.00 USD
-42,300.00 USD
Jan 1, 2025
0.00 USD
-154,000.00 USD
-101,200.00 USD

ACRO Biomedical Co Margins

ACRO Biomedical Co stock margins

The ACRO Biomedical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ACRO Biomedical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ACRO Biomedical Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
10.36 %
6.49 %
5.24 %
Jan 1, 2019
10.37 %
-32.59 %
-27.41 %
Jan 1, 2020
23.19 %
-18.84 %
-17.39 %
Jan 1, 2021
21.67 %
-640.83 %
-641.67 %
Jan 1, 2022
21.21 %
-2,404.55 %
-2,404.55 %
Jan 1, 2023
21.21 %
- %
- %
Jan 1, 2024
21.21 %
- %
- %
Jan 1, 2025
21.21 %
- %
- %

ACRO Biomedical Co Stock analysis

What does ACRO Biomedical Co do? ACRO Biomedical Co Ltd is a leading company in biomedical technology based in Taipei, Taiwan. The company was established in 2006 and has since successfully established itself in the global market for biomedical products and technologies. The company's vision is to improve people's lives and promote health worldwide through innovative and high-quality products and solutions. Business model: ACRO Biomedical Co Ltd specializes in the development, manufacturing, and marketing of biomedical products and technologies. The company has three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology. Each division focuses on developing products and solutions tailored to the needs of patients and medical professionals. Regenerative Medicine: ACRO Biomedical Co Ltd is a leading provider of regenerative biomedical products. Under this division, the company develops innovative solutions for tissue regeneration, such as bioimplants made from natural tissues and biomaterials to repair or restore damaged tissue. These products are used for the treatment of injuries, chronic diseases, and degenerative conditions. Additionally, ACRO Biomedical Co Ltd has also developed solutions for cosmetic and aesthetic applications. Wound Care: ACRO Biomedical Co Ltd's wound care division specializes in developing products and solutions that help accelerate wound healing, prevent infections, and reduce the risk of complications. The company offers a wide range of products, including antimicrobial and moist wound dressings, which are used for the treatment of acute and chronic wounds such as burns, abrasions, and diabetic foot ulcers. Surgical Technology: ACRO Biomedical Co Ltd's surgical technology division provides healthcare professionals with a wide range of surgical products for various applications, including neurosurgery, plastic surgery, and general surgery. The innovative products offered by ACRO Biomedical Co Ltd for surgical applications include cutting tools, implants, and instruments for minimally invasive procedures. Products: ACRO Biomedical Co Ltd offers a wide range of products for various applications and medical specialties. Some of the company's key products include: - ACL-Bioimplant: A bioimplant for cruciate ligament repair made from human cartilage and biomaterials. - ACRO-CAF: A bone grafting material for bone transplantation. - ACRO-Mixtop: A wound healing agent for the treatment of burns, abrasions, and chronic wounds. - ACRO-OSTEOT: A surgical bone drill for orthopedics and neurosurgery. - ACRO-BioSIS: A tissue adhesive for surgical applications. Summary: ACRO Biomedical Co Ltd is a leading company in biomedical technology that offers innovative solutions for the preservation and restoration of people's health. With its three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology, the company provides a wide range of products and solutions for medical professionals and patients. The company's products are marketed worldwide and are known for their quality, reliability, and effectiveness. ACRO Biomedical Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing ACRO Biomedical Co's EBIT

ACRO Biomedical Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of ACRO Biomedical Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

ACRO Biomedical Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in ACRO Biomedical Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about ACRO Biomedical Co stock

EBIT of ACRO Biomedical Co is -154,000.00 USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — ACRO Biomedical Co

All Key Metrics — ACRO Biomedical Co